@article{881212672a474647b9bc838bb03e2ccf,
title = "Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma: outcomes from a multicenter US-based systemic sclerosis registry",
abstract = "Abstract: The Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma is a multicenter US-based longitudinal study of patients with systemic sclerosis (SSc) within 5 years of first non-Raynaud{\textquoteright}s symptom. The data collection methodology incorporates successful models from other SSc registries. The cohort is designed to provide linked bio-specimen and clinical outcomes data on a longitudinal cohort of SSc patients for validation of hypothesis-driven research and to provide a platform for studying patient-reported outcomes in scleroderma. The CONQUER registry was developed using the guidelines of the International Society for Biological Repositories, and was an iterative process between physicians with an expertise in SSc, patient stakeholders, and information technology experts. Enrollment commenced in June 2018. During the first 6 months of the CONQUER Scleroderma study, 151 SSc patients with less than 5 years of disease duration (from first non-Raynaud{\textquoteright}s symptom) have been recruited. The mean age is 51 ± 14 years, 83% are female, and 60% of patients have diffuse disease. Survey completion rates are above 88% for all patient-reported outcome surveys. Bio-specimen collection rates are over 97%, and disease severity score completion rates are over 98%. Pulmonary function test data is available on 91% of patients, and echocardiography is available 80%. The CONQUER scleroderma study provides a unique and growing resource for studying scleroderma in a longitudinal, US-based population. Key Points: • The Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma is a multicenter US-based longitudinal study of patients with systemic sclerosis (SSc) within 5 years of first non-Raynaud{\textquoteright}s symptom. • The CONQUER scleroderma study provides a unique and growing resource for studying scleroderma in a longitudinal, US-based population. • CONQUER is innovative in its design in that it is focused on prospective collection of paired clinical and patient outcome data with bio-specimens.",
keywords = "Bio-specimens, Cohort study, Patient-reported outcomes, Prospective study, Registry, Systemic sclerosis",
author = "Shanmugam, {Victoria K.} and Frech, {Tracy M.} and Steen, {Virginia D.} and Hummers, {Laura K.} and Shah, {Ami A.} and Bernstein, {Elana J.} and Dinesh Khanna and Gordon, {Jessica K.} and Castelino, {Flavia V.} and Lorinda Chung and Hant, {Faye N.} and Emily Startup and VanBuren, {John M.} and Evnin, {Luke B.} and Shervin Assassi",
note = "Funding Information: VKS receives research funding from Abbvie Pharmaceuticals. TMF has no conflict of interest to disclose. VDS has received research funding from CSL Behring, and consultancy fees from Bayer, Boehringer Ingelheim, CSL Behring, Cytori and Genetech/Roche. She is on the Data Safety and Monitoring Board for Corbus and Galapagos. LKH receives research funding from Boehringer-Ingelheim, Eicos, Glaxo Smith Klein, Cumberland Pharmaceuticals and Corbus Pharmaceuticals and is on the medical advisory board for Boehringer-Ingelheim and CSL Behring. AAS serves on a data safety monitoring board for Sanofi. EJB receives grant support from Pfizer. DK has received research funding from Bayer, BMS, Horizon and Pfizer, as well as consultancy fees from Acceleron, Actelion, Bayer, BMS, Boehringer Ingelheim, Celgene, Corbus, CSL Behring, Cytori, Genetech/Roche and Sanofi. DK owns stock in Eicos Sciences, Inc., and is employed by the University of Michigan and CiviBioPharma, Inc. JKG has research funding from Eicos, Cumberland Pharmaceuticals and Corbus Pharmaceuticals. FVC has received consultancy fees from Boehringer-Ingelheim and Genentech. LC receives research funding from United Therapeutics, serves on the Data Safety Monitoring Board for Reata, and has received consultancy fees from Bristol-Myers Squibb, Boehringer-Ingelheim, Eicos and Mitsubishi Tanabe. FNH has no conflict of interest to disclose. ES has no conflict of interest to disclose. JMV has no conflict of interest to disclose. LBE is Chairman of the Board of the Scleroderma Research Foundation (a volunteer, uncompensated position) and is co-founder and co-owner of MPM Capital, which has invested in various biopharmaceutical companies; LBE represents MPM Capital on the Board of Directors for each of Blade Therapeutics, Tizona Therapeutics, Oncorus, Frontier Medicines, Werewolf Therapeutics, TwentyEight-Seven Therapeutics and Amphivena Therapeutics. LBE owns stock directly in Eicos Sciences, and affiliate of CiVi Biopharma. SA received grant support from Bayer, Boehringer-Ingelheim, Biogen and Momenta, consultancy fees from Boehringer-Ingelheim, and speaking fees from Integrity Continuing Education and Medscape. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Funding Information: The CONQUER scleroderma registry would not be possible without the team at the Utah Data Coordinating Center, including Anna Jolley, Juhee Sung-Schenck, and Michelle Robinson, as well as the lead research coordinators at each site, including Derek Jones (GW), Marianna Stark (Stanford), Rachel Broderick (Columbia), Ana Fernandes (MGH), Trevor Faith (MUSC), Sabrina Elliott (GU), Madeline Myers and Gwen Leatherman (Johns Hopkins), Maya Sabbagh and Sara Jaffar (UofM) and Julianne Hall (Utah), Samuel Theodore and Julio Charles (UTHSC-H). Funding Information: The CONQUER Scleroderma Study is supported by the Scleroderma Research Foundation, and the Scleroderma Research Foundation has received financial support from Boehringer Ingelheim and Actelion for the CONQUER Scleroderma Study. TMF is supported by awards from the National Institutes of Health (NIH) K23AR067889 and the U.S. Department of Veterans Affairs I01 CX001183. DK is supported by NIH/NIAMS K24 AR063120. LKH, AAS and LC receive funding from the Scleroderma Research Foundation. AAS is supported by NIH R01AR073208. EJB is supported by NIH K23AR075112. SA is supported by the DoD (W81XWH-16-1-0296). Publisher Copyright: {\textcopyright} 2019, International League of Associations for Rheumatology (ILAR).",
year = "2020",
month = jan,
day = "1",
doi = "10.1007/s10067-019-04792-y",
language = "English (US)",
volume = "39",
pages = "93--102",
journal = "Clinical rheumatology",
issn = "0770-3198",
publisher = "Springer London",
number = "1",
}